InvestorsObserver
×
News Home

Novavax Inc (NVAX) Stock: What Does the Chart Say Wednesday?

Wednesday, February 01, 2023 03:37 PM | InvestorsObserver Analysts

Mentioned in this article

Novavax Inc (NVAX) Stock: What Does the Chart Say Wednesday?

Novavax Inc (NVAX) stock is up 0.09% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,neutral
Novavax Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on NVAX!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With NVAX Stock Today?

Novavax Inc (NVAX) stock is trading at $11.12 as of 3:33 PM on Wednesday, Feb 1, a gain of $0.21, or 1.92% from the previous closing price of $10.91. The stock has traded between $10.13 and $11.14 so far today. Volume today is 8,249,770 compared to average volume of 7,877,959. To screen for more stocks like Novavax Inc click here.

More About Novavax Inc

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population. Click Here to get the full Stock Report for Novavax Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App